Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
PYPD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $5.09
Previous CloseN/A
Volume10.68K
Average Volume (3M)10.14K
Market Cap
$26.50M
Enterprise Value$16.73M
Total Cash (Recent Filing)$3.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
May 07, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.98
Shares Outstanding10,190,904
10 Day Avg. Volume8,886
30 Day Avg. Volume10,144
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.18
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$11.75Price Target Upside351.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
PolyPid News
PremiumCompany Announcements
PolyPid Ltd. Earnings Call Highlights Promising Prospects
PremiumCompany Announcements
PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe DSMB recommended the SHIELD II trial be upsized to 800 subjects, indicating a meaningful signal of benefit for D-PLEX100.
Financial PositionPolyPid's cash runway is extended through top-line pivotal results, expected to support operations into the third quarter of 2025.
Partnership OpportunitiesThe company is in active discussions with multiple potential commercial partners for D-PLEX100, with a focus on the U.S. opportunity.
Regulatory ProcessD-PLEX100 has Fast Track and Breakthrough designations, with management planning to submit the NDA on a rolling basis.
Bears Say
Stock Price TargetThe 12-month price target has been adjusted to $11 from $14 to account for the equity dilution resulting from the recent financing.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $2.30 and its highest was $5.09 in the past 12 months.
What is PolyPid Ltd.’s market cap?
PolyPid Ltd.’s market cap is $26.50M.
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is May 07, 2025 which is in 10 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on Feb 12, 2025. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$0.924 by -$0.206.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -0.82.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 10,190,904 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$1.13 in its last earnings report, missing expectations of -$0.924. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Currently, no hedge funds are holding shares in PYPD
---
PolyPid Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (351.92% Upside)
$11.75 (351.92% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.90%
12-Months-Change
Fundamentals
Return on Equity
-1038.73%
Trailing 12-Months
Asset Growth
64.06%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
---
PYPD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented positive developments, particularly regarding the SHIELD II trial's DSMB recommendation, successful financing, and partnership efforts, which suggest promising future prospects for D-PLEX100. However, increased expenses and net losses highlight ongoing financial challenges.Read More>---
PYPD Stock 12 Month Forecast
Average Price Target
$11.75
▲(351.92% Upside)
Technical Analysis
Pluri
―
Collplant Holdings
―
Grace Therapeutics
―
VYNE Therapeutics
―
Aligos Therapeutics
―
Best Analysts Covering PYPD
1 Year
1 Year Success Rate
0/29 ratings generated profit
1 Year Average Return
-57.43%
reiterated a buy rating 2 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.43% per trade.
---